The authors assess use of the novel assistant physician (AP) pathway and examine Missouri regulatory changes. They find limited supply impacts of APs and discuss implications.
David Schwartzman, PhD
Advertisement
Articles by David Schwartzman, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
3
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
4
Study Finds Flaw in Method for Key Oncology Value-Based Care Model
5